COREALIS Pharma expands its operations into a new facility in Laval (Qc) Canada

COREALIS Pharma expands its operations into a new facility in Laval (Qc) Canada

Laval, Quebec - April 16th, 2010 - COREALIS Pharma, Inc. (Corealis) announced today the consolidation of its operations by acquiring a new 33,000 square-foot state-of-the-art pharmaceutical research facility in the heart of the Cité de la Biotech in Laval (Qc), Canada. In addition, Corealis Pharma is hiring highly skilled scientists and purchasing complementary analytical and manufacturing equipments. These important investments made by Corealis are part of its ongoing strategic development plan in order to continue to be recognized as the reference in oral solid dosage formulation development.

According to Dr. Yves Roy, President of Corealis Pharma: "In the last few years, we have had to decline projects on a regular basis. With these investments, we will now be able to consolidate all of our services under one roof, tighten our project timelines, increase our capacity, reduce our operating costs and triple our yearly capacity. To our customers, this means shorter development time for their drug products.  As a result, they will get noticed faster by large Pharma for potential acquisition or partnership. We strive to make our clients succeed and I believe that we have now taken actions that will further help them achieve their goals! »

COREALIS is maintaining all the existing quality systems active in the facility to offer services that comply with the Canadian (Health Canada), US (US FDA) and European (EMEA) Pharmaceutical Good Manufacturing Practices requirements.

About COREALIS Pharma, Inc. - COREALIS Pharma is a private company whose three executive owners are involved in all aspects of the client projects. Corealis Pharma provides services on a contractual basis for Formulation and Process Development as well as for Clinical Trial Material (Phase I and II) Manufacturing and Packaging of oral solid dosage forms (tablets and capsules) to pharmaceutical and biotechnological companies. These services include: API characterization; Salt selection; Pre-formulation; Formulation and Process development; Analytical method development; cGMP Stability storage and testing; Technical transfer and Scale-up; cGMP Manufacturing and Packaging of Phase I and II CTM; Technical support for USA, Europe and Canadian submissions. The primary objective of Corealis and its staff is to make every client succeed.

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.